

Drugs in R&D.  
DUP - General Collection  
W1 DR893TC  
v. 6, no. 4  
2005

# Drugs<sup>TM</sup> R&D

2005, Vol. 6, No. 4 (pp. 189-252)  
ISSN: 1174-5886

Research Perspectives  
Policosanol  
Eslicarbazepine  
Fixed-Dose Orphenadrine plus Diclofenac  
Polyethylene Glycol 3350 plus Electrolytes




PROPERTY OF THE  
NATIONAL  
LIBRARY OF  
MEDICINE

Available Online

**adis**  
INTERNATIONAL

# Drugs<sup>™</sup> in R&D

*Timely information on  
emerging drug classes  
and new treatments*



Drugs in R&D  
is indexed in  
MEDLINE INDEXED

## Subscribe Today!

*Drugs in R&D* gives you rapid access to information on emerging drug classes and new treatments for specific disorders, allowing healthcare decision makers to keep up-to-date with clinically applicable knowledge about the likely place in therapy of new drugs.

### *Drugs in R&D* features:

- Original research with a strong link to clinical practice from all phases of drug development
- R&D drug profiles on new drugs from their first stages of development up to launch that summarise:
  - key drug properties
  - development phase by country and indication
  - analysis of commercial potential

All articles undergo peer review by international experts.

*Drugs in R&D* is indexed in: Index Medicus/MEDLINE, EMBASE/Excerpta Medica, the Chemical Abstracts Service (CAS) and International Pharmaceutical Abstracts (IPA).

To subscribe to this journal or to order a sample copy please  
e-mail: [Subs@nz.adis.com](mailto:Subs@nz.adis.com) or visit [www.adisonline.info](http://www.adisonline.info) for further details.

[www.adisonline.info](http://www.adisonline.info)

PERSONAL SUBSCRIPTION RATE \$230

**Contents**

<b>Original Research Articles</b>	Comparison of the Analgesic Effects of a Fixed-Dose Combination of Orphenadrine and Diclofenac (Neodolpasse®) with its Single Active Ingredients Diclofenac and Orphenadrine: A Placebo-Controlled Study Using Laser-Induced Somatosensory-Evoked Potentials from Capsaicin-Induced Hyperalgesic Human Skin <i>K Schaffler, P Reitmeir, A Gschanes, U Eggenreich</i>	189-199
	Effect of Food on the Pharmacokinetic Profile of Eslicarbazepine Acetate (BIA 2-093) <i>J Maia, M Vaz-da-Silva, L Almeida, A Falcão, P Silveira, S Guimarães, P Graziela, P Soares-da-Silva</i>	201-206
	Effects of Addition of Policosanol to Omega-3 Fatty Acid Therapy on the Lipid Profile of Patients with Type II Hypercholesterolaemia <i>G Castaño, L Fernández, R Mas, J Illnait, R Gámez, S Mendoza, M Mesa, J Fernández</i>	207-219
<b>Short Communication</b>	A Randomised, Controlled Comparison of Low-Dose Polyethylene Glycol 3350 plus Electrolytes with Ispaghula Husk in the Treatment of Adults with Chronic Functional Constipation <i>H-J Wang, X-M Liang, Z-L Yu, L-Y Zhou, S-R Lin, M Geraint</i>	221-225
<b>Adis R&amp;D Profile</b>	BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, Second-Generation Fumarate Derivative – Fumapharm/Biogen Idec	229-230
	Clindamycin/Tretinoin: Clindamycin Phosphate/Tretinoin Gel	231-234
	Hexyl Aminolevulinate: 5-ALA Hexylester, 5-ALA Hexylester, Aminolevulinic Acid Hexyl Ester, Hexaminolevulinate, Hexyl 5-Aminolevulinate, P 1206	235-238
	Icatibant: HOE 140, JE 049, JE049	239-244
	Lubiprostone: RU 0211, SPI 0211	245-248
Rufinamide: CGP 33101, E 2080, RUF 331, Xilep	249-252	

Register for the free Adis Electronic Table of Contents E-Mail Alert Service today at [www.adisonline.info](http://www.adisonline.info)

*Drugs in R&D* is indexed in the following biomedical databases: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, International Pharmaceutical Abstracts (IPA) and the Chemical Abstracts Service (CAS). Individual articles are available through the ADONIS® Document Delivery Service and online via the World Wide Web through Ingenta. Further details are available from the publisher.

**International Editorial Board**

- G. Amsden**, Cooperstown, NY, USA  
**S.E. Bellibas**, Nutley, NJ, USA  
**E. Beghi**, Milan, Italy  
**S. Bloomfield**, Cincinnati, OH, USA  
**A. Bryskler**, Paris, France  
**E. Christophers**, Kiel, Germany  
**M.J. Eadle**, Brisbane, QLD, Australia  
**D. Furst**, Seattle, WA, USA  
**L.C. Groop**, Malmo, Sweden  
**F. Horak**, Vienna, Austria  
**B.D. Kahan**, Houston, TX, USA  
**R. Kawamori**, Tokyo, Japan  
**M.G. Kris**, New York, USA  
**M. Lader**, London, UK  
**K. McCormack**, Leighton Buzzard, UK  
**J. Hamilton-Miller**, London, UK  
**T. Morgan**, Melbourne, VIC, Australia  
**G. Morris III**, Milwaukee, WI, USA  
**G. Moyle**, London, UK  
**P. Nathan**, Melbourne, VIC, Australia  
**D.J. Nutt**, Bristol, UK  
**E. Perucca**, Pavia, Italy  
**S.C. Schachter**, Boston, MA, USA  
**M.A. Smith**, Cleveland, OH, USA  
**F. Vajda**, Melbourne, VIC, Australia  
**C.J. van Boxtel**, Amsterdam,  
The Netherlands  
**H. van Leusden**, Oosterbeek,  
The Netherlands  
**J. Wilson**, Shreveport, LA, USA  
**V. Wong**, Hong Kong  
**N. Yuen**, Apex, NC, USA

**Aim and Scope:** The aim of *Drugs in R&D* is to provide timely information on: (i) emerging drug classes; and (ii) new treatments for specific disorders. Original research from all phases of clinical development is included, with a strong link to clinical practice. Healthcare decision makers are thus provided with clinically applicable knowledge about the likely place in therapy of a drug.

Journal issues comprise:

- Original research, including clinical trials with an emphasis on optimum clinical use and pharmacokinetic and pharmacodynamic studies in patients and healthy volunteers.
- R&D drug profiles including: (i) key drug properties; (ii) drug development phase by country and indication; (iii) analysis of commercial potential.

All articles are subject to peer review by international experts.

**Publication Manager:** Lorna Venter-Lewis

**Editorial Office and Inquiries:** Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand. Information on the preparation of manuscripts will be provided to authors.

E-mail: [DrugsR&D@adis.co.nz](mailto:DrugsR&D@adis.co.nz)

<http://www.adisonline.info/rdd>

*Drugs in R&D* (ISSN 1174-5886) is published bi-monthly by Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand. The annual 2005 institutional subscription price for print and online is \$US735 and for online only is \$US725. The personal subscription price for print and online is \$US230 and for online only is \$US225. All online subscriptions include access to online archived articles. Further subscription information is given at the back of each issue.

**Policy Statement:** Although great care has been taken in compiling the content of this publication, the publisher and its servants are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Opinions expressed do not necessarily reflect the views of the Publisher, Editor or Editorial Board.

**Copyright:** © 2005 Adis Data Information BV. All rights reserved throughout the world and in all languages. No part of this publication may be reproduced, transmitted or stored in any form or by any means either mechanical or electronic, including photocopying, recording, or through an information storage and retrieval system, without the written permission of the copyright holder.

The appearance of the code at the top of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for the personal or internal use of specific clients. This consent is given provided that the fee of \$US34.95 per copy is paid directly to the Copyright Clearance Center Inc., 222 Rosewood Drive, Danvers, Massachusetts 01923, USA, for copying beyond that permitted by sections 107 or 108 of the US Copyright Law. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

## Editorial Policies and Procedures for Submitted Original Research

### Aim of Submitted Original Research

The aim of original research articles in *Drugs in R&D* is to emphasise the role of rational clinical pharmacotherapy in optimising outcomes. This is accomplished by rapid publication of submitted original research covering all phases of clinical drug development and therapeutic use of drugs. In addition, short communications and case study reports that meet these criteria may be considered for publication, along with letters to the Journal Editor.

### Types of Submitted Original Research

Specific types of original research considered for publication in *Drugs in R&D* include clinical trials, outcomes research, clinical pharmacoeconomic studies, pharmacoepidemiology studies with a strong link to optimum prescribing practice for a drug or group of drugs, clinical pharmacodynamic and clinical pharmacokinetic studies with a strong link to clinical practice and, in some instances, pharmacodynamic or pharmacokinetic studies in healthy volunteers, but in which some established or purported implications for clinical prescribing are discussed.

### Potential Conflicts of Interest

Independent internationally recognised experts are sought in the first instance when seeking referees for articles. However, it is not always possible to determine the relationship between authors and the pharmaceutical industry in advance. Authors and peer reviewers are required to disclose potential conflicts of interest. Possible conflicts of interest are identified whenever practicable and this information is published prominently. Sources of article funding are also disclosed.

### Peer Review

The aim of the peer review process is to ensure publication of unbiased, scientifically accurate and clinically relevant articles that reflect international consensus of current opinion. All articles are subject to peer review by members of the Journal's international Editorial Board and/or other specialists of equal repute before a decision on publication is made. Revised manuscripts may be

reviewed a second time if appropriate. The final decision on acceptability for publication lies with the Journal Editor. The Editor of *Drugs in R&D* endorses the Consolidated Standards of Reporting Trials (CONSORT) guidelines for improving the quality of reporting of randomised controlled trials. The CONSORT statement, checklist and flow diagram have been adopted by the Journal to guide initial selection and peer review of original research articles submitted to *Drugs in R&D*. For more information on the CONSORT statement, checklist and flow diagram readers can visit the relevant World Wide Web site (<http://www.ama-assn.org>).

### Technical Editing

All articles are edited by an experienced and technically qualified Adis International editor. This process includes: (i) assessment of scientific accuracy, balance and completeness; (ii) choice of optimum structure; and (iii) general publishing considerations, such as house style and clarity of expression.

### Duplicate Publication

In general, material that has been previously published or accepted for publication elsewhere is not knowingly accepted for inclusion. The occasional decision to republish material in full or in part is made with reader interest in mind and requires the permission of the copyright holder. Prior publication is prominently acknowledged.

### Drug Nomenclature

Brand names or tradenames are generally not used, except in instances where the use of the generic name would be impractical or ambiguous. Appearance of a brand name or tradename does not imply endorsement of the product.

### Copyright

All authors are required to read and sign the statement on copyright transfer to Adis Data Information BV that is sent to them prior to publication.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.